The downgrade from Buy to Hold by Deutsche Bank indicates a less optimistic outlook for Moderna's stock. The lowered price target from $200 to $125 also suggests that the bank expects the stock's value to decrease in the short term. This could potentially lead to a decrease in the stock's price as investors adjust their expectations.